H. Cohen
Director/Board Member chez Paragon Biosciences LLC
Fortune : 561 408 $ au 31/03/2024
Profil
H.
Michael Cohen is currently the Director at Paragon Biosciences LLC.
He was previously the Lead Independent Director at Masimo Corp.
from 2018 to 2023.
He also served as a Director at Imbria Pharmaceuticals, Inc. Mr. Cohen holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Vermont.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MASIMO CORPORATION
0,01% | 26/05/2023 | 3 823 ( 0,01% ) | 561 408 $ | 31/03/2024 |
Postes actifs de H. Cohen
| Sociétés | Poste | Début |
|---|---|---|
Paragon Biosciences LLC
 Paragon Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Paragon Biosciences LLC is a life science innovator that creates, invests in, and builds life science companies in biopharmaceuticals, cell and gene therapy, and synthetic biology utilizing artificial intelligence. Paragon Biosciences is based in Chicago, IL, and has subsidiaries in the United States. The private company's current portfolio includes Castle Creek Biosciences, Circ Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences Holdings, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the Paragon Innovation Capital™ model. The company's mission is to solve complex human and societal challenges by creating and supporting focused, visionary companies that accelerate the development of novel therapies and life science breakthroughs. The company was founded by Jeffrey S. Aronin, who has been the CEO since incorporation. | Director/Board Member | 01/01/2018 |
Anciens postes connus de H. Cohen
| Sociétés | Poste | Fin |
|---|---|---|
| MASIMO CORPORATION | Director/Board Member | 26/06/2023 |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Director/Board Member | - |
Formation de H. Cohen
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| University of Vermont | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MASIMO CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
Paragon Biosciences LLC
Paragon Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Paragon Biosciences LLC is a life science innovator that creates, invests in, and builds life science companies in biopharmaceuticals, cell and gene therapy, and synthetic biology utilizing artificial intelligence. Paragon Biosciences is based in Chicago, IL, and has subsidiaries in the United States. The private company's current portfolio includes Castle Creek Biosciences, Circ Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences Holdings, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the Paragon Innovation Capital™ model. The company's mission is to solve complex human and societal challenges by creating and supporting focused, visionary companies that accelerate the development of novel therapies and life science breakthroughs. The company was founded by Jeffrey S. Aronin, who has been the CEO since incorporation. | Commercial Services |
